Cargando…

Incidence of Acute Kidney Injury Among Intensive Care Unit Patients Receiving Vancomycin in Combination with Cefepime or Piperacillin–Tazobactam

BACKGROUND: Combination therapy with piperacillin-tazobactam (TZP) and vancomycin (VAN) has been associated with increased AKI incidence when compared with cefepime (FEP) and VAN. However, this was not seen in critically ill patients, we hypothesized that critically ill patients receiving TZP+VAN wo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rutter, W Cliff, Burgess, David S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631209/ http://dx.doi.org/10.1093/ofid/ofx163.799

Ejemplares similares

Impact of Obesity on Acute Kidney Injury Incidence Among Patients Treated with Piperacillin–Tazobactam and Vancomycin
por: Rutter, W Cliff, et al.
Publicado: (2017)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

50. Comparative Incidence of Acute Kidney Injury in Septic Patients Treated with Vancomycin in Combination with Piperacillin/Tazobactam vs. Cefepime
por: Deja, Erin, et al.
Publicado: (2020)

1382. Acute Kidney Injury with Piperacillin–tazobactam and Vancomycin in the Intensive Care Unit
por: Smith, Tameka, et al.
Publicado: (2018)

Is There a Significant Difference in Acute Kidney Injury Incidence Among Patients Treated with Vancomycin Combined with Cefepime or Meropenem?
por: Rutter, W Cliff, et al.
Publicado: (2017)

Progression of kidney injury with the combination of vancomycin and piperacillin-tazobactam or cefepime in sepsis-associated acute kidney injury
por: Whitenack, Kaylee, et al.
Publicado: (2022)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

2292. Incidence of Acute Kidney Injury Associated with Duration of Vancomycin and Piperacillin/tazobactam Combination Therapy
por: McMullen, Lisanne, et al.
Publicado: (2019)

2221. Comparison of Vancomycin with Either Piperacillin/Tazobactam or Cefepime for the Incidence of Acute Kidney Injury in a Patient Population with a High Prevalence of Preexisting Kidney Dysfunction
por: Moran, Ryan, et al.
Publicado: (2023)

Comparison of Rates of Acute Kidney Injury with Vancomycin/Piperacillin-Tazobactam vs. Vancomycin/Meropenem Combination Therapy
por: Pernia, Sonia, et al.
Publicado: (2017)

2436. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter
por: Go, James, et al.
Publicado: (2018)

2576. Piperacillin-Tazobactam or Cefepime for Treatment of Third Generation Cephalosporin Resistant Pneumonia in Intensive Care Unit Patients
por: DeLaurentis, Clare, et al.
Publicado: (2023)

726. Risk factor analysis for cefepime and piperacillin/tazobactam resistant organisms
por: Pham, Tho H, et al.
Publicado: (2023)

80. Pharmacoeconomic Analysis Comparing the Empiric Utilization of Cefepime Versus Piperacillin/tazobactam
por: Olmack, Kelsey, et al.
Publicado: (2020)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

2669. Evaluation of Post-Operative Acute Kidney Injury with Piperacillin–Tazobactam Combined with Vancomycin for Lung Transplant Prophylaxis
por: Pettit, Natasha N, et al.
Publicado: (2019)

1335. A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin–Tazobactam
por: Pais, Gwendolyn M, et al.
Publicado: (2019)

400. Comparison of Tolerance and Microbiological Efficacy of Cefepime and Piperacillin/Tazobactam in Combination with Vancomycin as Empirical Antimicrobial Therapy of Prosthetic Joint Infection: A Propensity-Matched Cohort Study
por: Triffault-Fillit, Claire, et al.
Publicado: (2019)

Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/Tazobactam: Are Extended Infusions to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2015)

2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
por: Rathod, Shardul, et al.
Publicado: (2019)

212. Effectiveness of Empirical Piperacillin/tazobactam Compared to Cefepime for Bloodstream Infection Caused by Gram-Negative Bacilli
por: Ho Lee, Young, et al.
Publicado: (2023)

A Comparison Between Cefepime and Piperacillin-Tazobactam in the Management of Septic Shock
por: Ross, Robert C, et al.
Publicado: (2021)

Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia
por: Kim, Bo-Guen, et al.
Publicado: (2023)

A retrospective cohort study assessing acute kidney injury and renal recovery among septic patients empirically treated with vancomycin piperacillin–tazobactam versus vancomycin cefepime
por: Elliott, Brian Pacca, et al.
Publicado: (2021)

232. Impact of Weekend Initiation of Vancomycin or Piperacillin/Tazobactam on Days of Therapy Received upon Hospital Admission
por: McGregor, Jessina C, et al.
Publicado: (2020)

The association of high Vancomycin trough concentration with acute kidney injury during combination therapy of Piperacillin/Tazobactam and Vancomycin
por: Saito, Syuichiro, et al.
Publicado: (2022)

2432. Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit
por: Tucker, Kendall, et al.
Publicado: (2018)

Acute kidney injury in villous cancer patients treated with vancomycin and tazobactam/piperacillin
por: Nakatani, Kaori, et al.
Publicado: (2022)

2893 B. Effect of Cefepime versus Piperacillin-Tazobactam in Adults Hospitalized with Acute Infection: A Randomized Clinical Trial
por: Qian, Edward, et al.
Publicado: (2023)

1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
por: Aslan, Abdullah Tarik, et al.
Publicado: (2018)

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

Piperacillin/tazobactam/vancomycin: Cast nephropathy: case report
Publicado: (2022)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
por: Martin Mena, Anthony, et al.
Publicado: (2023)

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
por: Al Nuhait, Mohammed, et al.
Publicado: (2018)

Comparison of Acute Kidney Injury During Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem
por: Cannon, John M., et al.
Publicado: (2017)

Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study
por: Kadomura, Shota, et al.
Publicado: (2019)

Piperacillin/tazobactam/vancomycin: Clostridium difficile colitis: case report
Publicado: (2021)

248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
por: Son, Andrea, et al.
Publicado: (2020)

Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy
por: Kim, Tiffany, et al.
Publicado: (2015)

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ca230soo33nhq6ueu1fmjmv6vp